National Health Act 1953 - Amendment determination under sections 85, 85A and 88 - pharmaceutical benefits (No. PB 87 of 2009)

Overview

The National Health Act 1953, enacted by the Australian Parliament, serves as the legislative foundation for the Pharmaceutical Benefits Scheme (PBS). This Act aims to ensure reliable, timely, and affordable access to a wide range of medicines for all Australians. Through legislative instruments, the Minister is authorised to determine various aspects of pharmaceutical benefits, including the forms, brands, and prescribing conditions of drugs and medicinal preparations. The explanatory statement for instrument number PB 87 of 2009, which came into effect on 1 October 2009, outlines amendments made to determinations under sections 85, 85A, and 88 of the Act. These amendments, based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), involve adding and deleting brands and forms of pharmaceutical items, as well as altering prescribing conditions. The PBAC, an independent expert body, plays a critical role in recommending which drugs should be available as pharmaceutical benefits, considering factors such as clinical effectiveness, safety, and cost-effectiveness.

Scope and Application

The National Health Act 1953, as amended by the legislative instrument PB 87 of 2009, establishes the framework for the Pharmaceutical Benefits Scheme (PBS) and applies to pharmaceutical benefits provided by the Commonwealth for all Australians. The Act authorises the Minister for Health to make various determinations regarding the forms, brands, and administration of listed drugs, as well as the prescribing practices for pharmaceutical benefits. These determinations are made through legislative instruments that list specific drugs and medicinal preparations, their forms, brands, and the conditions under which they can be prescribed and administered. This legislative instrument, which commenced on 1 October 2009, amends previous determinations by adding new brands and forms of drugs to the PBS, altering existing forms and brands, and removing certain forms and brands from the list. The amendments are based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), which ensures a formal and ongoing consultation process involving various stakeholders. The Act applies nationally across Australia, covering entities and individuals who are eligible for pharmaceutical benefits under the PBS. The instrument also provides for the exclusion of certain drugs and forms from the PBS, reflecting decisions made by the PBAC regarding the clinical effectiveness, safety, and cost-effectiveness of treatments.

Key Provisions

The National Health Act 1953, through its Part VII, establishes the Pharmaceutical Benefits Scheme (PBS), which is the legislative foundation for the Commonwealth's provision of accessible, timely, and affordable medication for all Australians (subsection 85(1)). The Minister has the authority to declare by legislative instrument specific drugs and medicinal preparations that qualify for PBS coverage, as outlined in subsection 85(2). These declared drugs and preparations are referred to as "listed drugs" (subsection 84(1)). The Act also mandates that the Minister determines the form of a listed drug, including its strength, type of unit, and size, by legislative instrument (subsection 85(3)). Additionally, the Minister can specify the administration method of a listed drug form (subsection 85(5)), and determine the brand of a pharmaceutical item, defined as the trade name of the supplier or, in the absence of a trade name, the supplier's name (subsection 84(1), subsection 85(6)). The Act imposes several obligations on the parties involved. The Minister must determine the form, administration method, and brand of pharmaceutical items as per the provisions outlined in subsections 85(3), 85(5), and 85(6). Furthermore, the Minister is authorised to set limits on the quantity, repetition, and administration methods in prescriptions written by specific classes of persons for pharmaceutical benefits (subsection 85A(2)). This includes determining the maximum quantity or number of units that may be supplied in one prescription, the maximum number of occasions for repeating the supply, and the permissible methods of administration (subsection 85A(2)(a), (b), and (c)). The Minister also has the authority to specify the pharmaceutical benefits for which a dental practitioner is authorised to write a prescription (subsection 88(1A)). Breaches of the provisions under the National Health Act 1953 may result in various legal consequences. The Act does not explicitly detail specific offences or penalties within the provided text. However, in general terms, violations of legislative instruments or ministerial determinations under the Act could potentially lead to civil or criminal proceedings, depending on the nature and severity of the breach. Penalties could range from fines to more severe sanctions, including imprisonment, although the exact penalties would be determined by the courts based on the specific circumstances of each case. The Act relies on the broader legal framework to enforce compliance and address breaches effectively.